Skip to main content
Equibles
DSGN logo

DSGN · Design Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track DSGN — free

Use DSGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DSGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.63 -0.17 (-1.15%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$915.57M
Shares
62.58M

Design Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Design Therapeutics, Inc. (DSGN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$17.71M '25 Q1 25-05-07 LATEST · $ −$17.64M '26 Q1 26-04-28
Conference
Investor event
2026-06-04
Design Therapeutics, Inc. (DSGN) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-18
Design Therapeutics, Inc. (DSGN) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call
Revenue
$
Diluted EPS
$-0.29
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-11-05
Design Therapeutics, Inc. (DSGN) Q3 2025 Earnings Call Transcript
Confident tone Friedreich's Ataxia (FA) clinical data Muscle frataxin expression Study design and disclosure timing
Diluted EPS
$-0.30
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Design Therapeutics, Inc. (DSGN) Q1 2025 Earnings Call Transcript
Confident tone mFARS clinical data and dose response Dose exploration beyond 1 MPK Friedreich's Ataxia clinical proof-of-concept
Revenue
$
Diluted EPS
$-0.31
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript
Confident tone Friedreich Ataxia Program (DT-216 / DT-216P2) GeneTAC Platform Differentiation Pharmacokinetics and Formulation Improvements
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q1
2022-05-09
Design Therapeutics, Inc. (DSGN) Q1 2022 Earnings Call
Diluted EPS
$-0.24
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-11-09
Design Therapeutics, Inc. (DSGN) Q3 2021 Earnings Call
Diluted EPS
$-0.21
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts CIK 1807120 CUSIP 25056L103 13F (30d) 60 filings 60 filers Visit website Investor relations